文献速递水电解质与酸碱

尿素与托伐普坦治疗住院SIADH患者的比较

Urea vs. tolvaptan for hospitalized patients with SIADH.
PubMed 文献 · Nephrol Dial Transplant · 2026-07-15

该回顾性队列研究纳入537例SIAD(血钠<130 mmol/L)住院成人,比较尿素与托伐普坦的疗效与安全性。两组达到血钠>130 mmol/L的比例相似(79.7% vs 78.0%,P=0.986),但托伐普坦48小时血钠升幅更大、过度纠正更多、费用更高。提示尿素可能疗效相当且更安全、经济。

要点

  • 尿素与托伐普坦达到血钠>130 mmol/L的比例相似。
  • 托伐普坦48小时血钠升幅更大但过度纠正风险更高。
  • 尿素治疗费用显著低于托伐普坦。

核心结论

  • 尿素与托伐普坦疗效可能相当,但尿素过度纠正更少且费用显著更低。

研究设计与样本

  • 单中心回顾性队列研究,纳入2015年1月至2023年12月成人SIAD住院患者,使用逆概率治疗加权调整混杂因素。

主要发现

  • 537例患者中463例接受尿素(中位年龄78岁,57%女性,基线血钠124.2 mmol/L,起始剂量26±6.1 g/日),74例接受托伐普坦(68岁,56%女性,123.6 mmol/L,起始剂量12.9±6.5 mg/日)。
  • 达到血钠>130 mmol/L的比例相似(79.7% vs 78.0%,P=0.986)。
  • 托伐普坦48小时血钠升幅更大(8.3 vs 5.6 mmol/L,P=0.001),但过度纠正(>10 mmol/L/24小时)更多(10.8% vs 3.2%,P=0.011)。
  • 托伐普坦治疗时间更长(7 vs 5天,P=0.001),费用更高(€468 vs €12,P<0.001)。

关键数值与推荐

  • SIAD定义为血清钠<130 mmol/L。
  • 主要结局为达到血清钠>130 mmol/L的比例。
  • 过度纠正定义为>10 mmol/L/24小时。

临床怎么用

  • 对于合适的SIAD住院患者,尿素可作为安全且经济的一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Hyponatremia is the most common electrolyte disorder found in hospitalized patients and is associated with an increased mortality. Urea has been proposed as an alternative to vasopressin receptor antagonists (VRA) in the treatment of SIAD though comparative data are scarce. The aim was to evaluate the effectiveness and safety of urea compared with tolvaptan for treating SIAD in hospitalized patients. METHODS: Retrospective cohort study of adult inpatients with SIAD (serum sodium <130 mmol/L) treated with either urea or tolvaptan at a single institution between January 2015 and December 2023. Inverse probability of treatment weighting adjusted for confounders. Primary outcome was the proportion of patients achieving a serum sodium of >130 mmol/L. Secondary outcomes included time to treatment goal, serum sodium changes at 24, 48, and 72 hours, proportion of overcorrection (>10 mmol/L per 24 hours) and resource utilization. RESULTS: Of 537 patients, 463 received urea (median age 78 years; 57% female; baseline serum sodium 124.2 mmol/L, mean starting dose: 26 ± 6.1 g daily) and 74 received tolvaptan (68 years; 56% female; 123.6 mmol/L, mean starting dose 12.9 ± 6.5 mg daily). Similar proportions reached a serum sodium >130 mmol/L (79.7% vs 78.0%, P = 0.986). Time to target showed a trend favoring tolvaptan (2 (IQR 1-4) vs 3 (IQR 2-5) days, P = 0.077). Tolvaptan produced faster sodium increases at 48 hours (8.3 (IQR 4.4-12.0) vs. 5.6 (IQR 2.9-9.0) mmol/L), P = 0.001) but also more overcorrections (>10 mmol/L per 24 hours: 10.8% vs 3.2%, P = 0.011). Treatment duration was longer with tolvaptan (7 (IQR 4-11) vs 5 (IQR 3-8) days, P = 0.001), with substantially higher costs (€468 vs €12, P < 0.001). CONCLUSIONS: Urea may have a comparable effectiveness to tolvaptan with similar success rates but fewer overcorrections and substantially lower costs. These findings support urea as a safe and cost-effective first-line treatment option for appropriate patients with SIAD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Heller M, Marx K, Hoffmann U, et al. Urea vs. tolvaptan for hospitalized patients with SIADH. Nephrol Dial Transplant. 2026. PMID: 42455009. doi:10.1093/ndt/gfag165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。